Chrystal Paulos, Professor and Co-leader of the Cancer Immunology Program at Winship Cancer Institute of Emory University, shared a post on LinkedIn:
“New Publication in The Journal of Immunology
Excited to share our latest work:
“Development of a murine TIL therapy model for cholangiocarcinoma”
The challenge: Cholangiocarcinoma (CCA) is a lethal, immune-refractory cancer. While TIL therapy is FDA-approved for melanoma, translating it to CCA has been hampered by the lack of a rigorous preclinical model.
What we accomplished:
Established the first orthotopic murine model of TIL therapy for CCA
Developed a tumor antigen–guided TIL expansion method that produced T cells with better killing capacity and persistence than conventional CD3-expanded TILs
Demonstrated that TIL therapy combined with PD-L1 blockade significantly delayed tumor growth and improved survival, pointing toward rational combination strategies for patients
Team science at its best:
This project was driven by co–first authors Megen Wittling and Frances Bennett, with key contributions from Emilie Warren, Kailey Oppat, Megan Wyatt, Jacklyn Hammons, Yuan Liu, Shishir Maithel, and many others.
Proud to serve as co–corresponding author alongside Gregory Lesinski on this effort.”
Title: Development of a murine tumor-infiltrating lymphocyte therapy model for cholangiocarcinoma
Authors: Megen C Wittling, Frances J Bennett, Emilie A K Warren, Kailey M Oppat, Megan M Wyatt, Jacklyn N Hammons, Yuan Liu, Shishir K Maithel, Chrystal M Paulos, Gregory B Lesinski
Read the Full Article.
More posts featuring Chrystal Paulos on OncoDaily.